Discontinued — last reported Q4 '25
Year-over-year, this metric declined by 100.0%, from $100.00M to $0.00. Over 4 years (FY 2021 to FY 2025), Acquisitions shows a downward trend with a -30.6% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $27.00M | $0.00 | $1.52B | $7.50M | $7.50M | $7.50M | $7.50M | $91.25M | $91.25M | $91.25M | $91.25M | $0.00 | $0.00 | $126.00M | $9.00M | $100.00M | $254.00M | $6.00M | $0.00 | $0.00 |
| QoQ Change | — | -100.0% | — | -99.5% | +0.0% | +0.0% | +0.0% | >999% | +0.0% | +0.0% | +0.0% | -100.0% | — | — | -92.9% | >999% | +154.0% | -97.6% | -100.0% | — |
| YoY Change | — | — | — | — | -72.2% | — | -99.5% | >999% | >999% | >999% | >999% | -100.0% | -100.0% | +38.1% | -90.1% | — | — | -95.2% | -100.0% | -100.0% |